share_log

ALLARITY THERAPEUTICS INC | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

SEC announcement ·  Apr 8 12:38
Summary by Moomoo AI
Allarity Therapeutics, Inc. (Allarity) has announced an offering of up to 26,569,246 shares of common stock, alongside an equal number of Series A and Series B common warrants, and pre-funded warrants to purchase shares of common stock. The offering also includes up to 53,138,492 shares of common stock issuable upon the exercise of Series A and Series B common warrants, and up to 26,569,246 shares of common stock issuable upon the exercise of pre-funded warrants. The exercise price for the warrants will be determined based on the public offering price of the shares. The securities are being offered through a placement agent on a reasonable best-efforts basis. The placement agent is not purchasing the securities but will attempt to arrange...Show More
Allarity Therapeutics, Inc. (Allarity) has announced an offering of up to 26,569,246 shares of common stock, alongside an equal number of Series A and Series B common warrants, and pre-funded warrants to purchase shares of common stock. The offering also includes up to 53,138,492 shares of common stock issuable upon the exercise of Series A and Series B common warrants, and up to 26,569,246 shares of common stock issuable upon the exercise of pre-funded warrants. The exercise price for the warrants will be determined based on the public offering price of the shares. The securities are being offered through a placement agent on a reasonable best-efforts basis. The placement agent is not purchasing the securities but will attempt to arrange for their sale. The offering is subject to market conditions, and there is no assurance that the entire amount of securities will be sold. The proceeds from the offering are intended for general corporate purposes, including working capital and operational expenses. The offering's terms and conditions are detailed in a registration statement filed with the Securities and Exchange Commission (SEC).

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more